Tables of Link
==============

  TARGETS                             
  ----------------------------------- -----------------------
  **Catalytic receptors***^a^*[@b2]   **Enzymes***^b^*[@b2]
  Integrin α2β1                       COX
  Integrin αIIbβ3                     PI3K
  Collagen receptor                   PKB (Akt)
                                      PKG
                                      PLCγ2
                                      sGC
                                      Syk

  LIGANDS        
  -------------- -----------------------
  ADP            Luteolin
  Apigenin       LY294002
  Aspirin        Nitric oxide (NO)
  ATP            ODQ
  cGMP           Quercetin
  Clopidogrel    Thrombin
  Collagen       TXA2
  Fibrinogen     von Willebrand factor
  Indomethacin   

These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson *et al*., [@b32]) and are permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (*^a,b^*Alexander *et al*., 2013a,b).

Introduction
============

Platelet activation is initiated upon binding of various ligand molecules to their cognate cell surface receptors, which trigger intracellular signalling cascades that lead to shape change, release of granule contents, thromboxane A~2~ (TXA~2~) synthesis and release and thrombus formation (Gibbins, [@b13]). A number of currently available anti-thrombotic drugs (e.g. aspirin and clopidogrel) are hampered by associated side effects including severe bleeding (Barrett *et al*., [@b4]; Mackman, [@b24]; Michelson, [@b28]), and therefore, the development of safer, more efficacious and target-specific drugs to prevent thrombosis is a pressing priority. The association between diet and cardiovascular disease is well established (Wright *et al*., [@b42]). Epidemiological studies (Middleton *et al*., [@b29]; Joshipura *et al*., [@b19]; Hubbard *et al*., [@b17]; Benavente-Garcia and Castillo, [@b5]; Hooper *et al*., [@b15]) have suggested that regular intake of foods rich in flavonoids can reduce cardiovascular disease risks. Indeed, dietary flavonoids have been shown to inhibit platelet function, reduce lipid levels and maintain vascular integrity, which may underpin a reduced risk of cardiovascular diseases. The complex nature of the mechanism of action of plant flavonoids on the cardiovascular system including platelets has initiated research to better understand the basis of the relationship between these dietary components and cardiovascular health in order to develop more effective strategies to prevent or treat thrombotic diseases (Wright *et al*., [@b42]).

Since extracts from citrus fruits, particularly lemons (*Citrus limon*) are widely used in traditional medications in India and China, we sought to explore the importance of flavonoids which are abundant in citrus fruits on platelet function. Nobiletin is a highly abundant flavonoid present in these and is structurally similar to tangeretin, another abundant flavonoid in such sources (Benavente-Garcia and Castillo, [@b5]). Nobiletin has been shown to have several beneficial effects on different cell types including anti-proliferative and anti-apoptotic properties on cancer cells (Akao *et al*., [@b1]; Chen *et al*., [@b9]), and inhibitory effects on inflammation (Wu *et al*., [@b43]). Nobiletin has been shown to reduce the adhesive properties of platelets (Sempinska *et al*., [@b35]; Robbins, [@b34]), although the mechanisms through which this occurs and its potential to reduce thrombus formation have not been explored previously. In a previous study, we reported that tangeretin inhibits platelet function and thrombus formation via elevation of cGMP and inhibition of PI3K signalling (Vaiyapuri *et al*., [@b38]). In this study, we demonstrated that nobiletin is a potent inhibitor of platelet function that acts through similar effects on platelet function, and established these mechanisms as common modes of action which flavonoids may share in order to modulate the function of these cells.

Methods
=======

Detailed methods for immunoblotting analysis, cyclic nucleotide, flow cytometry, clot retraction, platelet spreading, *in vitro* thrombus formation and tail bleeding assays are provided in Supporting Information [Appendix S1](#sd1){ref-type="supplementary-material"}.

The animal welfare and ethical statement
----------------------------------------

All animals (C57BL/6 mice) were used following appropriate approval from the University of Reading Local Ethics Review Panel and a license from the British Home Office accordance with the Animal (Scientific Procedures) Act 1986. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny *et al*., [@b20]; McGrath *et al*., [@b27]). Nobiletin or vehicle control was administered blindly, and the number of mice required was calculated based on previous studies within the authors\' laboratory (Vaiyapuri *et al*., [@b38]). Every animal used in the experiments was included in the analysis (no exclusions were made). There were no adverse effects observed in mice infused with nobiletin.

Platelet preparation, aggregation and dense granule secretion
-------------------------------------------------------------

Human platelet preparation and aggregation assays were performed using standard protocols. After informed consent had been obtained, blood was collected from healthy, aspirin-free human volunteers into a syringe containing 4% citrate (1:10 ratio). The citrated whole blood was mixed with an equal volume of physiological saline (0.9% NaCl) and was used for impedance aggregometry. The blood was centrifuged for 20 min at 102× *g* at room temperature to obtain platelet-rich plasma (PRP) for aggregation, flow cytometry, clot retraction and cyclic nucleotide assays. Further centrifugation of PRP \[with 125 ng·mL^--1^ prostaglandin I~2~ (PGI~2~)\] at 1413× *g* for 10 min resulted in a platelet pellet that was re-suspended in modified Tyrodes-HEPES buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na~2~HPO~4~·12H~2~O, 12 mM NaHCO~3~, 20 mM HEPES and 1 mM MgCl~2~, pH 7.3) and washed by centrifuging again at the same speed for 10 min. The resulting platelet pellet was re-suspended in modified Tyrodes-HEPES buffer to a final density of 4 × 10^8^ cells·mL^−1^ for aggregation and ATP secretion assays.

Platelet aggregation assays were performed by optical aggregometry using cross-linked collagen-related peptide \[CRP-XL, a selective agonist for the platelet collagen receptor glycoprotein (GP) VI, from Prof R Farndale (University of Cambridge)\], collagen (Horm collagen, Nycomed, Linz, Austria) and thrombin (Sigma Aldrich, Poole, UK) in the presence or absence of various concentrations of nobiletin (Sigma Aldrich; dissolved in DMSO to prepare stock solutions). The final concentration of DMSO used as required was 0.01% (v/v), which did not affect platelet function and was used as vehicle control. Similarly, dense granule secretion was measured by monitoring the level of ATP released from washed platelets upon activation with CRP-XL using a luciferin-luciferase luminescence substrate (Chrono-log, Havertown, PA, USA) by luminescence aggregometry. All the aggregation assays (optical, impedance and luminescence) were performed using Chrono-Log Model 700 Whole Blood/Optical-Lumi Aggregometer.

Statistical analysis
--------------------

The data obtained from aggregation, fibrinogen binding, α-granule secretion and *in vitro* thrombus formation assays were analysed using non-parametric repeated measures [anova]{.smallcaps} (Friedman test). Median fluorescence intensity values obtained with fibrinogen binding and α-granule secretion assays were converted into percentages for comparison of controls with nobiletin-inhibited samples. Data obtained from dense granule secretion, clot retraction, spreading and cyclic nucleotide assays were analysed using parametric repeated measures [anova]{.smallcaps}. Data from calcium mobilization experiments were analysed by 'R' statistical software and the percentage of maximum level of calcium release was analysed using non-parametric repeated measures [anova]{.smallcaps} (Friedman test). Tail bleeding assay data were analysed using *t*-test. All the statistical analyses were performed using GraphPad Prism (version 5.04) from GraphPad Software Inc. (La Jolla, CA, USA).

Results
=======

Nobiletin inhibits human platelet activation
--------------------------------------------

Optical aggregometry was used to analyse the effects of nobiletin on platelet function upon activation with collagen, CRP-XL and thrombin. Washed human platelets were incubated with vehicle (0.01% DMSO) or nobiletin (6.25, 12.5, 25, 50 and 100 μM) for 5 min before stimulation with collagen (1 μg·mL^−1^) for up to 5 min (Figure [1A](#fig01){ref-type="fig"}) in an optical aggregometer. Nobiletin reduced platelet aggregation in a concentration-dependent manner at 5 min (Figure [1A](#fig01){ref-type="fig"} and [B](#fig01){ref-type="fig"}) with 95% inhibition achieved at 100 μM. The inhibitory effects of nobiletin were reduced modestly when a higher concentration of collagen (5 μg·mL^−1^) was used (Figure [1C](#fig01){ref-type="fig"} and [D](#fig01){ref-type="fig"}). Since collagen activates platelets by binding both glycoprotein VI (GPVI) and integrin α2β1, a GPVI-selective agonist, CRP-XL, was used in aggregation assays to determine whether the inhibition of platelet aggregation occurred through the blockade of GPVI signalling. Platelet aggregation stimulated with CRP-XL (0.5 μg·mL^−1^) was also inhibited by nobiletin in a concentration-dependent manner (Figure [1E](#fig01){ref-type="fig"} and [F](#fig01){ref-type="fig"}). Similar to collagen, a higher concentration of CRP-XL (1 μg·mL^−1^) reduced the level of inhibition induced by nobiletin (Figure [1G](#fig01){ref-type="fig"} and [H](#fig01){ref-type="fig"}). In order to determine whether nobiletin is able to affect the signalling cascades activated by G-protein coupled receptors, aggregation assays were performed using thrombin as an agonist. A concentration of 0.1 U·mL^−1^ of thrombin was chosen to obtain similar levels of aggregation as obtained with other agonists such as collagen (1 μg·mL^−1^) and CRP-XL (0.5 μg·mL^−1^). Thrombin (0.1 U·mL^−1^)-stimulated platelet activation was inhibited by nobiletin only at higher concentrations (50, 100, 150 and 200 μM; Figure [1I](#fig01){ref-type="fig"} and [J](#fig01){ref-type="fig"}). Lower concentrations of nobiletin did not inhibit thrombin-induced platelet aggregation (data not shown).

![Nobiletin inhibits agonist-induced platelet activation. Human-washed platelet aggregation performed in the presence or absence of various concentrations of nobiletin was monitored for 5 min by optical aggregometry following stimulation with 1 μg·mL^−1^ (A and B) and 5 μg·mL^−1^ collagen (C and D), 0.5 μg·mL^−1^ (E and F) and 1 μg·mL^−1^ CRP-XL (G and H) and 0.1 U·mL^−1^ thrombin (I and J). Similarly, the effects of nobiletin on PRP were analysed following stimulation with 1 μg·mL^−1^ collagen (K and L). Indomethacin (10 μM)-treated platelets were stimulated with 0.5 μg·mL^−1^ CRP-XL in the presence and absence of nobiletin (M and N). Whole blood aggregation was performed using 10 μg·mL^−1^ collagen in the presence and absence of nobiletin by impedance aggregometry (O and P). Cumulative data represent mean values ± SD (*n* = 3), the level of aggregation obtained at 5 min with vehicle-treated samples (0 μM) was taken as 100%. The *P*-values shown in the figure are calculated by non-parametric repeated measures [anova]{.smallcaps} (Friedman test; \*\*\*\**P* \< 0.0001).](bph0172-4133-f1){#fig01}

Some dietary flavonoids such as quercetin (Wright *et al*., [@b42]) and tangeretin (Vaiyapuri *et al*., [@b38]) have been shown to bind plasma proteins, and therefore, the effect of nobiletin on platelet activation in PRP was examined to compare its effects with washed platelets. Collagen (1 μg·mL^−1^)-induced platelet aggregation in PRP was inhibited by nobiletin in a concentration-dependent manner to a similar extent to that observed with washed platelets (Figure [1K](#fig01){ref-type="fig"} and [L](#fig01){ref-type="fig"}). This suggests that the effects of nobiletin at this concentration are not adversely affected by the presence of plasma proteins. To understand if the effects of nobiletin in collagen-induced platelet aggregation are dependent on secondary activation mediated through molecules that are synthesized and released from platelets, further aggregation assays were performed using indomethacin (an inhibitor of COX, which prevents TXA~2~ synthesis)-treated washed platelets. CRP-XL (0.5 μg·mL^−1^)-induced aggregation was reduced significantly by nobiletin in indomethacin (10 μM)-treated platelets (Figure [1M](#fig01){ref-type="fig"} and [N](#fig01){ref-type="fig"}) indicating that the effects of nobiletin are not fully dependent on the inhibition of the effects of secondary mediators such as TXA~2~. To further understand the effects of nobiletin in whole blood in the presence of other cells such as red blood cells and leukocytes, impedance aggregometry was performed. Collagen at a concentration of 10 μg·mL^−1^ was used to obtain a similar level of aggregation to 1 μg·mL^−1^ in washed platelets. Despite the higher concentration of collagen, nobiletin (50 μM and above) reduced aggregation significantly (Figure [1O](#fig01){ref-type="fig"} and [P](#fig01){ref-type="fig"}). These analyses together indicate that nobiletin predominantly inhibits GPVI-stimulated platelet activation, although it is able to modulate platelet activation induced by other agonists such as thrombin, at higher concentrations.

Integrin αIIbβ3-mediated inside-out signalling is modulated by nobiletin
------------------------------------------------------------------------

Platelet inside-out signalling to integrin αIIbβ3 plays an essential role in the modulation of its conformation to increase affinity for plasma fibrinogen and von Willebrand factor (vWF) binding and consequent platelet aggregation (Calderwood, [@b8]). In order to explore the effects of nobiletin in inside-out signalling that leads to the modulation of integrin αIIbβ3 affinity, fibrinogen binding was measured by flow cytometry in the presence or absence of nobiletin. Consistent with platelet aggregation, CRP-XL (1 μg·mL^−1^)-induced fibrinogen binding in PRP was inhibited significantly at all concentrations of nobiletin used (6.25, 12.5, 25, 50, 100 and 200 μM; Figure [2A](#fig02){ref-type="fig"} and Supporting Information [Fig. S1A](#sd1){ref-type="supplementary-material"}).

![Nobiletin modulates platelet inside-out signalling, granule secretion and calcium mobilization. The effect of nobiletin on CRP-XL (1 μg·mL^−1^)-induced fibrinogen binding (A) and P-selectin exposure (B) in PRP was measured by flow cytometry. The median fluorescence intensity values were converted into percentages for comparison. The level of fibrinogen binding or P-selectin exposure with vehicle controls was taken as 100%. Data represent mean ± SD (*n* = 5) and the *P*-values shown were calculated using non-parametric repeated measures [anova]{.smallcaps} (Friedman test). Similarly, the effect of nobiletin on dense granule secretion upon stimulation with CRP-XL (1 μg·mL^−1^) was measured in washed platelets (C and D). The level of ATP obtained with vehicle controls was taken as 100%. Data represent mean ± SD (*n* = 4) and the *P*-values shown were calculated using parametric repeated measures [anova]{.smallcaps}. Fluo4-NW dye labelled human PRP was stimulated with 1 μg·mL^−1^ CRP-XL in the presence of 50 or 100 μM nobiletin or vehicle control and the intracellular calcium levels were measured by flow cytometry (E). Traces shown are representative of four separate experiments. The inhibition of intracellular calcium levels was calculated by comparing the levels obtained at 5 min (F) in the presence or absence (taken as 100%) of nobiletin. Data represent mean ± SD (*n* = 4). The *P*-values shown in the figure were as calculated by using non-parametric repeated measures [anova]{.smallcaps} (Friedman test; \*\*\**P* \< 0.001 and \*\*\*\**P* \< 0.0001). AU represents arbitrary units.](bph0172-4133-f2){#fig02}

Nobiletin inhibits platelet granule secretion
---------------------------------------------

Platelet degranulation is an important step towards thrombus formation as the released granule contents enhance rapid activation of platelets through paracrine/autocrine actions (Gibbins, [@b13]). Platelet α-granules are rich in proteins such as fibrinogen, vWF and P-selectin and dense granules are rich in non-proteinaceous substances such as ADP, ATP and calcium. To assess the ability of nobiletin to inhibit platelet α-granule secretion, P-selectin exposure on the surface of platelets upon stimulation with CRP-XL was measured by flow cytometry. Different concentrations of nobiletin were pre-incubated with human PRP prior to activation with CRP-XL (1 μg·mL^−1^) and analysis of P-selectin exposure. Nobiletin inhibited significantly P-selectin exposure at all concentrations used in PRP (Figure [2B](#fig02){ref-type="fig"} and Supporting Information [Fig. S1B](#sd1){ref-type="supplementary-material"}). Maximal inhibition of approximately 50% was obtained with 200 μM nobiletin. Similarly, the level of ATP secreted from washed platelets assayed in parallel with aggregation was inhibited by nobiletin upon stimulation with CRP-XL (1 μg·mL^−1^) in a concentration-dependent manner (Figure [2C](#fig02){ref-type="fig"} and [2D](#fig02){ref-type="fig"}). The level of inhibition observed in dense granule secretion was larger than that of α-granule secretion, which is likely due to different conditions (washed platelets, stirring and 37°C for dense granule secretion; PRP, non-stirring and room temperature for α-granule secretion) used in these two assays. Together these data suggest that nobiletin is able to reduce platelet granule secretion and thereby control platelet activation.

Intracellular calcium mobilization is modulated by nobiletin
------------------------------------------------------------

An elevation of intracellular calcium levels in platelets is important for the regulation of thrombus formation, reorganization of the actin cytoskeleton necessary for shape change (Hathaway and Adelstein, [@b14]), degranulation and integrin αIIbβ3-mediated signalling (Shattil and Brass, [@b36]). To analyse the effects of nobiletin on intracellular calcium mobilization, this was measured in human platelets (PRP) by flow cytometry. CRP-XL (1 μg·mL^−1^)-activated cytoplasmic calcium levels were inhibited significantly by nobiletin (50 and 100 μM). Maximum inhibition of approximately 40% was achieved with 100 μM nobiletin (Figure [2E](#fig02){ref-type="fig"} and [2F](#fig02){ref-type="fig"}). The initial acceleration rate of calcium elevation was inhibited substantially by nobiletin (Figure [2E](#fig02){ref-type="fig"}). These data suggest that nobiletin affects the elevation of intracellular calcium levels to modulate platelet function.

Nobiletin affects integrin αIIbβ3-mediated outside-in signalling
----------------------------------------------------------------

Following binding to fibrinogen, integrin αIIbβ3 clustering transduces signals (outside-in signalling) into platelets to allow spreading and in the latter phase of its formation, clot retraction (Calderwood, [@b8]). The modulatory effects of nobiletin on integrin αIIbβ3-mediated outside-in signalling were analysed by measuring clot retraction and platelet spreading under static conditions. Clot formation was initiated by adding thrombin to PRP in the absence or presence of nobiletin (12.5, 25, 50 and 100 μM), and the rate of clot retraction was monitored over 2 h by measuring the remaining clot weight. Although the initial clot formation was normal in vehicle and nobiletin-treated samples, clot retraction was reduced significantly in the presence of nobiletin (100 μM) at 2 h compared with the control samples (Figure [3A](#fig03){ref-type="fig"} and [3B](#fig03){ref-type="fig"}). Similarly, nobiletin-treated (100 μM) platelets were unable spread on fibrinogen to a similar extent to control platelets at 45 min. Most nobiletin-treated platelets failed to progress beyond filopodia formation with only a few cells progressing to lamellapodia formation and full spreading (Figure [3C](#fig03){ref-type="fig"} and [3D](#fig03){ref-type="fig"}). These data suggest that outside-in signalling through integrin αIIbβ3, which controls the coordinated process of clot retraction and platelet spreading on fibrinogen, is affected by nobiletin.

![Integrin αIIbβ3-mediated outside-in signalling is inhibited by nobiletin. The effect of various concentrations of nobiletin (12.5, 25, 50 and 100 μM) on clot retraction was analysed *in vitro* using human PRP (A and B). (A) Representative image of clot retraction at 2 h in the presence or absence of different concentrations of nobiletin. Data in (B) represent mean ± SD (*n* = 4) of clot weights measured at 2 h. Washed human platelets were allowed to spread for 45 min in the presence and absence of 100 μM nobiletin on 100 μg·mL^−1^ fibrinogen-coated cover glasses and stained with Alexa fluor 488 labelled phalloidin prior to analysis using a Nikon A1-R-confocal microscope. The images shown in (C) are representative of multiple images acquired from four separate experiments. The images were analysed by ImageJ and the number of platelets found at different states of platelet spreading were calculated (D). The *P*-values were calculated using parametric repeated measures [anova]{.smallcaps} (\*\*\**P* = \<0.001 and \*\*\*\**P* = \<0.0001).](bph0172-4133-f3){#fig03}

Nobiletin limits thrombus formation *in vitro*
----------------------------------------------

Given the dramatic effects of nobiletin on platelet function, its effects on thrombus formation were assessed *in vitro* in whole blood under arterial flow conditions. Fluorescently labelled (DiOC~6~) human blood was pre-incubated with vehicle control or different concentrations of nobiletin (12.5, 25, 50 and 100 μM) and perfused over collagen-coated Vena8 biochips for 10 min at a shear rate of 20 dynes·cm^−2^. Normal progression of thrombus formation was observed in vehicle-treated samples, whereas a clear reduction in thrombus volume and fluorescence intensity (Figure [4A](#fig04){ref-type="fig"} and [4B](#fig04){ref-type="fig"}) was observed at all concentrations of nobiletin used. These data suggest that nobiletin is able to reduce both initial platelet adhesion and subsequent thrombus formation.

![Nobiletin limits thrombus formation *in vitro* and extends bleeding time in mice. DiOC~6~ labelled human blood was pre-incubated with vehicle or different concentrations of nobiletin and perfused over collagen-coated Vena8 BioChips. Images were obtained every 30 s for up to 10 min and representative images (at 0, 2, 4, 6, 8 and 10 min) are shown in (A). The fluorescence intensity of thrombi obtained in the absence of nobiletin was taken as 100% and compared with the levels obtained with different concentrations of nobiletin (B). Data represent mean ± SD (*n* = 4). The *P*-values shown in the figure are as calculated by non-parametric repeated measures [anova]{.smallcaps} (Friedman test; \*\*\*\**P* \< 0.0001). The effect of nobiletin (estimated 50 μM) on haemostasis in mice was analysed by measuring the bleeding time after removal of 1 mm of tail tip. The bleeding time obtained with vehicle-treated group was compared with nobiletin-treated mice (C). Data represent mean ± SD (*n* = 7 mice for vehicle control or nobiletin-treated group). The significance between control and treated groups, and the *P*-values were calculated by Student\'s *t*-test.](bph0172-4133-f4){#fig04}

Nobiletin extends bleeding time in mice
---------------------------------------

To analyse the effects of nobiletin on haemostasis, tail bleeding assays were performed on mice in the presence of vehicle \[DMSO (0.01%)\] or nobiletin (at estimated 50 μM concentration based on the mouse weight and respective volume of blood). Vehicle-treated mice bled between 98 and 372 s, whereas administration of nobiletin extended the bleeding to between 278 and 1200 s (Figure [4C](#fig04){ref-type="fig"}). Four of the seven nobiletin-treated mice bled for 1200 s (when the assay was terminated). These data suggest that nobiletin is able to modulate haemostasis in mice, consistent with the effects observed on thrombus formation.

Nobiletin blocks PKB (Akt) activation
-------------------------------------

Since collagen and CRP-XL-stimulated platelet activation was affected by nobiletin, the phosphorylation levels of different signalling proteins involved in the GPVI pathway were analysed. Washed human platelets were stimulated at 37°C in an aggregometer under conditions (in presence of 1 mM EGTA, 10 μM indomethacin and 2 U·mL^−1^ apyrase) that disfavour platelet aggregation with CRP-XL (1 μg·mL^−1^) in the presence of various concentrations of nobiletin (12.5, 25, 50, 100, 150 and 200 μM) or vehicle control, and lysates were prepared to analyse the phosphorylation of different signalling proteins. Total tyrosine phosphorylation (Figure [5A](#fig05){ref-type="fig"}) and the phosphorylation of individual proteins such as Syk (pY323) and LAT (pY200; Figure [5B](#fig05){ref-type="fig"}) were not affected by nobiletin. However, tyrosine phosphorylation of PLCγ2 (pY759) was diminished at all concentrations of nobiletin used (Figure [5B](#fig05){ref-type="fig"}). Similarly, the serine phosphorylation of PKB (or Akt) (pS473) was also affected in a concentration-dependent manner by nobiletin (Figure [5B](#fig05){ref-type="fig"}). Although the phosphorylation levels were quantified under non-aggregation conditions, the level of inhibition of phosphorylation of PLCγ2 and Akt were similar to the inhibitory effects observed on platelet aggregation at the same concentration of agonist (Figure [1G](#fig01){ref-type="fig"} and [1H](#fig01){ref-type="fig"}). For example, 12.5 μM of nobiletin inhibited around 20--30% of CRP-XL-induced platelet aggregation and phosphorylation of PLCγ2 and Akt. These data suggest that nobiletin may not influence the immediate effectors within the GPVI pathway (such as Syk and LAT) although it can modulate the later signalling events controlled by PLCγ2 and Akt, which are shared with activation mechanisms stimulated by other agonists. The inhibitory effects of nobiletin on PLCγ2 and Akt phosphorylation indicate its potential effect on PI3K-mediated platelet signalling.

![Nobiletin inhibits phosphorylation of PLCγ2 and PKB (Akt). Washed human platelets were stimulated with CRP-XL (1 μg·mL^−1^) in the absence or presence of various concentrations of nobiletin before the analysis by immunoblotting using anti-phosphotyrosine antibody (A) and phospho-specific antibodies for proteins involved in the GPVI pathway such as Syk pY323, LAT pY200, PLCγ2 pY759 and Akt pS473 (B). Total level of 14-3-3ζ was measured on each sample as a loading control. The blots shown in the figure are representative of four separate experiments. R represents resting platelets. Data presented in (B) represent mean ± SD (*n* = 4) and *P*-values were calculated using non-parametric repeated measures [anova]{.smallcaps} (Friedman test; \*\*\*\**P* \< 0.0001).](bph0172-4133-f5){#fig05}

Nobiletin elevates platelet cGMP levels
---------------------------------------

Under physiological conditions, endothelium-derived nitric oxide (NO) and PGI~2~ inhibit platelet function by elevating platelet cGMP and cAMP levels respectively. Since plant flavonoids such as tangeretin have been shown to act on cyclic nucleotide signalling (Ok *et al*., [@b30]), the effects of nobiletin on the levels of cGMP and cAMP in platelets were analysed in the presence of vehicle control or different concentrations (50, 100, 150 and 200 μM) of nobiletin. The levels of cGMP (Figure [6A](#fig06){ref-type="fig"}) and cAMP (Figure [6B](#fig06){ref-type="fig"}) were unaltered upon stimulation with CRP-XL (1 μg·mL^−1^), but the addition of nobiletin elevated cGMP levels significantly. Lower concentrations (less than 50 μM) of nobiletin did not increase the cGMP levels significantly (data not shown). cAMP levels, however, remained unaltered in the presence of all the concentrations of nobiletin used. To explore whether the elevation of cGMP levels by nobiletin is dependent on activation by CRP-XL, the level of cGMP was measured in resting platelets incubated with nobiletin (200 μM) for 5 min. Platelet cGMP levels were increased in platelets treated with nobiletin alone (Figure [6A](#fig06){ref-type="fig"}) indicating that cGMP elevation is not dependent on agonist stimulation or platelet activation. These data suggest that nobiletin may inhibit platelet function through the elevation of cGMP and not through cAMP.

![Nobiletin elevates cGMP levels and increases VASP (S239) phosphorylation. The levels of cGMP (A) and cAMP (B) were measured in platelets (PRP) upon stimulation with CRP-XL (1 μg·mL^−1^) using [elisa]{.smallcaps} kits in the presence or absence of various concentrations of nobiletin. The concentration of cGMP and cAMP was calculated based on standard curves. R, resting; C, CRP-XL-treated platelets. Data represent mean ± SD (*n* = 4) and *P*-values were calculated using parametric repeated measures [anova]{.smallcaps} (\*\*\*\**P* \< 0.0001). Platelet aggregation was measured using CRP-XL (0.5 μg·mL^−1^) together in the presence and absence of 20 μM ODQ, a soluble guanylate cyclase inhibitor (C and D) or 30 μM PKG inhibitor (*R*p-8-Br-PET-cGMPS) (E and F) and 50 μM nobiletin for 5 min. C, O, P and N represent CRP-XL, ODQ, PKG inhibitor and nobiletin respectively. The level of aggregation obtained with CRP-XL at 5 min was taken as 100% to calculate the percentage of inhibition. The data from C + N were compared with C and C + O/P + N were compared with C + N. Data represent mean ± SD (*n* = 3) and *P*-values were calculated using Student\'s *t*-test as shown (\*\**P* \< 0.01 and \*\*\**P* \< 0.001). The effect of various concentrations of nobiletin on phosphorylation of VASP \[at positions pS239 (G) and pS157 (H)\], a substrate for cyclic nucleotide-dependent PKs, was analysed in washed platelets upon stimulation with CRP-XL (1 μg·mL^−1^) by immunoblotting. The blots are representative of four separate experiments. Data represent mean ± SD (*n* = 4) and *P*-values were calculated using non-parametric repeated measures [anova]{.smallcaps} (Friedman test; \*\*\*\**P* \< 0.0001).](bph0172-4133-f6){#fig06}

To further understand the effects of nobiletin in platelets through the elevation of cGMP levels, aggregation assays were performed in the presence and absence of a soluble guanylate cyclase inhibitor ODQ and a cGMP-dependent PKG inhibitor (Rp-8-bromo-β-phenyl-1,N2-ethenoguanosine 3′,5′-cyclic monophosphorothioate sodium salt \[*R*p-8-Br-PET-cGMPS\]). Pre-incubation of platelets either with ODQ (20 μM) or the PKG inhibitor (30 μM) did not cause a reduction in CRP-XL (0.5 μg·mL^−1^)-induced platelet aggregation. However, both of these inhibitors reversed the inhibitory actions of nobiletin (50 μM) upon activation with CRP-XL (Figure [6C](#fig06){ref-type="fig"}--F). These data further confirm that the actions of nobiletin in platelets are at least in part explained by its ability to modulate cGMP signalling.

Vasodilator-stimulated phosphoprotein (VASP) is a substrate for cAMP- and cGMP-dependent PKs that mediate cAMP- and cGMP-dependent inhibitory signalling in platelets respectively (Butt *et al*., [@b7]; Li *et al*., [@b22]). Upon elevation of cAMP, the cAMP-dependent PKA phosphorylates VASP at position S157, whereas increased levels of cGMP result in phosphorylation of S239 in VASP by cGMP-dependent PKG (Li *et al*., 2003a,b[@b21],[@b22]). To confirm the ability of nobiletin to modulate cyclic nucleotide signalling, the phosphorylation of VASP was assessed using phospho-specific antibodies upon stimulation with CRP-XL (1 μg·mL^−1^). Immunoblot analysis showed that nobiletin increased the phosphorylation of VASP at S239 (Figure [6G](#fig06){ref-type="fig"}), but only small changes were observed in phosphorylation of position S157 (Figure [6H](#fig06){ref-type="fig"}). These data suggest that nobiletin may modulate the inhibitory signalling mediated through cGMP and PKG in platelets.

Discussion
==========

A better understanding of the relationship between plant flavonoids and platelet function may aid in the development of improved strategies to treat cardiovascular diseases. In this study, we characterized nobiletin, which is a polymethoxylated flavonoid structurally similar to tangeretin present in the peel of citrus fruits, and analysed its anti-platelet effects. Nobiletin was shown to have anti-adhesive properties in rat platelets (Sempinska *et al*., [@b35]; Robbins, [@b34]), and reduced death rates in rats by ADP induced thrombosis at 8 mM concentration (Robbins, [@b33]). However, these previous studies did not explore the mechanism of action through which nobiletin exerts its effects in platelets particularly in humans. In our previous study, we demonstrated the effects of a citrus flavonoid, tangeretin on the modulation of platelet function (Vaiyapuri *et al*., [@b38]). Tangeretin affected platelet function by elevating cGMP levels and inhibiting PI3K-mediated signalling cascades.

In this study, we report that nobiletin inhibited platelet activation upon stimulation with collagen and CRP-XL in a concentration-dependent manner with notable levels of reduction achieved at as low as 6.25 μM. Increasing concentrations of agonists were able to partially overcome the inhibitory effects of nobiletin, confirming that it does not show any toxic effects to the platelets. Platelet activation stimulated with a GPCR agonist, thrombin, was, however, only inhibited at higher concentrations of nobiletin (as high as 50 μM required to obtain a significant reduction) indicating that it has increased potency for the inhibition of GPVI dependent pathways. Similar inhibitory effects on GPVI and thrombin induced platelet activation were observed with tangeretin although at lower concentrations (Vaiyapuri *et al*., [@b38]). These results indicate that nobiletin may be less potent than tangeretin, although it maintained similar levels of inhibition in PRP in the presence of plasma proteins. A number of other plant-derived flavonoids such as quercetin, apigenin and luteolin have been shown to inhibit agonist-induced platelet aggregation at various concentrations (Hubbard *et al*., 2003; 2004[@b16],[@b17]; Lill *et al*., [@b23]; Wright *et al*., [@b41]). Consistent with the inhibition of aggregation, nobiletin was able to inhibit the affinity modulation of integrin αIIbβ3 to favour platelet aggregation. In addition, nobiletin inhibited platelet granule secretion similar to tangeretin and other flavonoids.

A number of flavonoids have been shown to inhibit several enzymes, which regulate normal cellular functions such as tyrosine kinases, phospholipase As (PLAs), lipoxygenases, COXs and phosphodiesterases (Benavente-Garcı\'a *et al*., [@b6]; Benavente-Garcia and Castillo, [@b5]; Wright *et al*., [@b42]). Quercetin and catechin were able to inhibit the phosphorylation of serine/threonine kinases, extracellular signal--related kinase 1/2, c-Jun N-terminal kinase, MAPK and Akt in vascular smooth muscle and endothelial cells (Wright *et al*., [@b42]). Similarly, the flavonoids present in purple grape juice were shown to partially inhibit the phosphorylation of PKC in platelets (Freedman *et al*., [@b11]). Since nobiletin inhibited collagen-induced platelet activation, further analyses of the signalling proteins involved in the GPVI pathway was performed and revealed that it did not affect early signalling effector molecules such as Syk and LAT. Nobiletin did however diminish the activation of later signalling modulators such as AKT and PLCγ2, both associated with PI3K signalling to regulate platelet function, particularly calcium mobilization. Consistent with diminished PI3K signalling, reduced calcium levels and subsequently retarded integrin αIIbβ3-mediated outside-in signalling (clot retraction and platelet spreading) were observed upon treatment with nobiletin. The inhibition of PLCγ2 and AKT by nobiletin was also observed in other cell types such as liver cancer cells (Shi *et al*., [@b37]). Together, these inhibitory effects of nobiletin resulted in reduced thrombus formation *in vitro* under arterial flow conditions.

Experiments to dissect the direct and indirect actions of these citrus flavonoids on the various components of PI3K signalling may reveal specific targets in the modulation of platelet function. The inhibition of PI3K signalling was also observed with other flavonoids such as quercetin (Matter *et al*., [@b26]), which led to the development of LY294002, a commonly used PI3K inhibitor (Vlahos *et al*., [@b39]). Due to the broad spectrum nature of flavonoids on different aspects of cell regulation (Wright *et al*., [@b42]), it is entirely possible for nobiletin to have other target mechanisms to inhibit platelet function. Flavonoids such as apigenin and luteolin have shown to antagonize TXA~2~ receptors in order to inhibit platelet function (Lill *et al*., [@b23]), and therefore, nobiletin may also have additional targets that may influence on the secondary activation of platelets.

The ability of flavonoids to inhibit phosphodiesterases (PDE; Wright *et al*., [@b42]), which are involved in the hydrolysis of cyclic nucleotides such as cAMP and cGMP (Francis *et al*., [@b10]), suggests that flavonoids may also modulate platelet function through other inhibitory mechanisms. Nobiletin increased the cGMP levels and VASP phosphorylation at S239, which is phosphorylated by PKG, while it neither increased the cAMP levels nor phosphorylation of VASP at S157, which is regulated by PKA. The increased levels of VASP phosphorylation may directly inhibit platelet function mediated through the phosphorylation of myosin light chain kinase resulting in impaired calmodulin binding and therefore reduce cytoskeletal reorganization essential for platelet shape change (Onselaer *et al*., [@b31]). In addition, VASP phosphorylation is able to inhibit the activation of integrin αIIbβ3 and suppress the release of intracellular calcium through inhibiting IP3 receptor activation (Geiger, [@b12]). We have previously shown that tangeretin was able to increase the levels of cGMP although it did not alter the cAMP levels or inhibit PDE activity (Vaiyapuri *et al*., [@b38]), indicating that tangeretin elevates cGMP levels through increased production rather than its reduced hydrolysis. Purple grape juice and flavonoid derivatives have been shown to increase platelet derived NO production in order to inhibit platelet function (Freedman *et al*., [@b11]). Elevated levels of NO in platelets are capable of causing an increase in cGMP levels, which in turn activate PKG to phosphorylate its substrate VASP at position S239 (Butt *et al*., [@b7]). It is presently unclear whether the effects that we observed are mediated by direct actions of nobiletin on NO production, or cGMP levels. It is presently unclear whether the effects of nobiletin on PI3K and cGMP signalling are mechanistically linked or whether they represent separate modes of action.

Better understanding of the structure--function relationships of flavonoids will reveal their selectivity for target molecules (Wright *et al*., [@b42]), and will also enable the understanding of differences between the specificity and efficiency of nobiletin and tangeretin. While structurally similar, a difference at an O-methyl group on the B ring results in considerable changes in their inhibitory effects observed in PRP, suggesting the importance of this methyl group in determination of its ability to bind plasma proteins.

The polymethylated structure of nobiletin has been suggested to maintain its stability and enable resistance against the metabolic changes such as alterations by the cytochrome P450 system, UDP-glucurosyltransferases and sulphotransferases (Walle, [@b40]). The most common metabolic changes observed in nobiletin are the demethylation on the C4 ring in its structure (Yasuda *et al*., [@b44]). The extended half-life of nobiletin compared with tangeretin in the circulation (Walle, [@b40]; Manthey *et al*., [@b25]) suggests this may be potentially administered in order to avail longer bioavailability.

In this study, we demonstrate that 12.5 μM nobiletin is able to significantly inhibit platelet function *in vitro* in washed platelets, PRP and whole blood. A concentration of 50 μM was shown to moderately affect haemostasis in mice. Tail bleeding assays were performed at 37°C by maintaining the animal on a heated mat. The use of anaesthetics may have effects on platelet function and therefore in haemostasis; however, the parallel comparison of vehicle control and nobiletin-treated mice alleviates this issue. A pharmacokinetic study previously reported (Manthey *et al*., [@b25]) that concentrations of tangeretin of around 6.2 μM (including known metabolites) and nobiletin 22.4 μM in rodents were achievable upon oral administration of 50 mg·kg^−1^ of body weight. This indicates that the ingestion of around 100 mg·kg^−1^ may reach approximately 50 μM of nobiletin in plasma and affect haemostasis to a similar extent to that observed in this study. As reported in the previous study, the bioavailability of nobiletin even after 12 h of oral administration was maintained above a concentration of approximately 5 μM. The half-life of nobiletin, however, upon the administration through the i.v. route has yet to be explored. Although one would imagine that it is unlikely for these levels of nobiletin and tangeretin to be achieved through regular dietary intake, many additional flavonoids are present in most diets. It may also be possible to achieve the required levels of these flavonoids by regular oral supplementation as suggested previously in rodents. Indeed, a pilot human study reported quercetin to reach 10 μM through oral dietary supplementation (Hubbard *et al*., [@b18]) and this suggests that the regular intake of nobiletin through supplementation might show similar effects, which we observed in mice upon i.v. infusion of nobiletin. Therefore, nobiletin and tangeretin, together with other bioactive flavonoids, may collectively modulate platelet function in order to reduce potential thrombosis risk. The effects of tangeretin and nobiletin, however, below the threshold of detection *in vivo*, may still be relevant. Chronic ingestion of nobiletin and tangeretin from diets may also result in a cumulative effect on the reduction of platelet function over a period of time. Diets rich in bioactive flavonoids also result in intake of a range of complex mixtures of various flavonoids such as quercetin, apigenin and luteolin that may also be beneficial in reducing cardiovascular disease incidence. We conclude that further investigation to explore the therapeutic potentials of nobiletin and tangeretin may enable the formulation of better therapeutic strategies to reduce cardiovascular disease risk.
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GPVI

:   glycoprotein VI
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:   soluble guanylate cyclase

VASP

:   vasodilator-stimulated phosphoprotein
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**Figure S1** Representative histograms show the level of fibrinogen binding (A) or P-selectin exposure (B) on the platelet surface in the absence and presence of various concentrations of nobiletin upon stimulation with 1 μg·mL^−1^ CRP-XL as measured by flow cytometry.

**Appendix S1** Methods.
